ReportWire

Tag: Medical Conditions

  • Two new COVID variants are spreading fast in New York region and could account for about 37% of new cases

    Two new COVID variants are spreading fast in New York region and could account for about 37% of new cases

    [ad_1]

    The two newly identified omicron subvariants, dubbed BQ.1 and BQ.1.1, are spreading fast in the New York region and could account for about 37% of new cases, according to Centers for Disease Control and Prevention data crunched by NBC News.

    The two variants accounted for 11.5% and 8% of new cases, respectively, that were recorded in the area in the week ending Oct. 15, up from 4.1% and 1.9% two weeks earlier. The New York area includes New Jersey, Puerto Rico and the Virgin Islands.

    Combined, they accounted for 11.4% of overall U.S. cases in the same week. Before last Friday’s data release, they were included in BA.5 variant data, as the numbers were too small to break out. BQ.1 was first identified by researchers in early September and has been found in the U.K. and Germany, among other places. The CDC is updating the numbers every Friday.

    “When you get variants like that, you look at what their rate of increase is as a relative proportion of the variants, and this has a pretty troublesome doubling time,” Anthony Fauci, President Joe Biden’s chief medical adviser, said in an interview with CBS News earlier this week.

    The news comes as experts fear another wave of cases during the winter months as colder weather forces people indoors and families gather for holidays.

    U.S. known cases of COVID are continuing to ease and now stand at their lowest level since mid-April, although the true tally is likely higher given how many people overall are testing at home, where the data are not being collected.

    The daily average for new cases stood at 37,888 on Tuesday, according to a New York Times tracker, down 15% from two weeks ago. Cases are currently rising in 10 states: Nevada, New Hampshire, New Mexico, Oklahoma, Maryland, Wisconsin, Illinois, Vermont, Kansas and Florida. Cases are also rising in Washington, D.C.

    The daily average for hospitalizations was down 6% to 25,845, although hospitalizations are up in many northeastern states, including Rhode Island, New Hampshire, New Jersey, New York, Massachusetts, Delaware, Pennsylvania and Maine.

    The daily average for deaths is down 3% to 382.

    In other news, the World Health Organization said its emergency committee came away from a meeting last week with the determination that the pandemic remains a global health emergency, despite recent progress.

    WHO Director General Tedros Adhanom Ghebreyesus said he agreed with that decison.

    “The committee emphasized the need to strengthen surveillance and expand access to tests, treatments and vaccines for those most at-risk, and for all countries to update their national preparedness and response plans,” Tedros told reporters at a briefing.

    “While the global situation has obviously improved since the pandemic began, the virus continues to change, and there remain many risks and uncertainties,” he said. “This pandemic has surprised us before and very well could again.”

    The new bivalent vaccine might be the first step in developing annual COVID-19 shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to COVID could be challenging. Illustration: Ryan Trefes

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Reports that a 16-year-old girl has died at a COVID quarantine center in China are causing anger after her family said their pleas for medical help were ignored, the Guardian reported. Videos of the girl have spread across Chinese social media in the last 24 hours. The distressing footage, which the Guardian said it has not been able to independently verify, shows the teenager ill, struggling to breathe and convulsing in a bunk bed at what is purported to be a quarantine center in Ruzhou, Henan province. The reports come as Communist Party leaders hold their party congress in Beijing amid anger about the country’s strict zero-COVID policy.

    • Hong Kong, which is experiencing a massive brain drain thanks to the pandemic and to political upheaval, unveiled a new visa scheme on Wednesday that aims to attract global talent, the Associated Press reported. The region’s chief executive, John Lee, said the Top Talent Pass Scheme will allow people who earn an annual salary of 2.5 million Hong Kong dollars ($318,472) or more, as well as graduates of the world’s top universities, to work or pursue opportunities in the city for two years.

    In a rare display of defiance, two banners unfurled from a highway overpass in Beijing condemned Chinese President Xi Jinping and his strict COVID policies. The protest took place days before the Communist Party congress in that city.

    • The COVID pandemic catalyzed a major shift in the way Americans live and work, and a new analysis from the Federal Reserve Bank of New York shows that workers in the U.S. are taking advantage of the widespread shift toward remote work to spend more time sleeping and engaging in leisure activities, MarketWatch’s Chris Matthews reported. “One of the most enduring shifts [resulting from the pandemic] has occurred in the workplace, with millions of employees making the switch to work from home,” wrote David Dam, a former New York Fed research analyst, in a Tuesday blog post.

    • The North Dakota Department of Health stored thousands of COVID-19 vaccine doses at incorrect temperatures or without temperature data over the past two years, according to a state audit Tuesday that said some of those vaccines were administered to patients, the AP reported. The health department disputed the findings. Tim Wiedrich, who heads the agency’s virus response, said “no non-viable vaccine” was given to patients. In responses that accompanied the audit, the department said clerical errors or other errors of documentation erroneously suggested that expired or bad doses were given.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 625.7 million on Wednesday, while the death toll rose above 6.57 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 97 million cases and 1,065,841 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 226.2 million people living in the U.S., equal to 68.1% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 110.8 million have had a booster, equal to 49% of the vaccinated population, and 25.6 million of those who are eligible for a second booster have had one, equal to 39% of those who received a first booster.

    Some 14.8 million people have had a dose of the updated bivalent booster that targets omicron and its subvariants along with the original virus.

    [ad_2]

    Source link

  • CDC identifies new COVID variants that accounted for 11.4% of new cases in week ending Oct. 15

    CDC identifies new COVID variants that accounted for 11.4% of new cases in week ending Oct. 15

    [ad_1]

    The Centers for Disease Control and Prevention said a new COVID variant dubbed BQ.1 and a descendant called BQ.1.1 have gained traction in the U.S., accounting for 11.4% of new cases across the nation in the week ending Oct. 15.

    The two variants are lineages of BA.5, the omicron subvariant that remains dominant but has shrunk to account for just 67.9% of circulating variants, the agency said in a Friday update. The CDC had previously combined BQ.1 and BQ.1.1 with BA.5 cases because the numbers of the new variants were so small. BQ.1 was first identified by researchers in early September and has been found in the U.K. and Germany, among other places.

    New York and New Jersey currently have the highest proportion of BQ.1 and BQ.1.1 infections, at about 20% of overall cases, according to CDC estimates.

    “When you get variants like that, you look at what their rate of increase is as a relative proportion of the variants, and this has a pretty troublesome doubling time,” Anthony Fauci, President Joe Biden’s chief medical adviser, said in an interview with CBS News. 

    Adding to concerns, the variant seems “to elude important monoclonal antibodies,” he added.

    Fauci is confident that Moderna
    MRNA,
    +3.92%
    ,
    as well as Pfizer
    PFE,
    +1.84%

    and German partner BioNTech
    BNTX,
    +2.45%
    ,
    will be able to update boosters to target the new subvariant. “The somewhat encouraging news is that it’s a BA.5 sublineage, so there are almost certainly going to be some cross-protections that you can boost up,” he said.

    So far, only 14.8 million people living in the U.S. have taken advantage of the new bivalent boosters that were authorized by the Food and Drug Administration in late August. That’s equal to about 7% of the 209 million who were initially eligible.

    The FDA authorized the Pfizer booster for use in people aged 12 and older and the Moderna booster for adults aged 18 and older. Last week, the FDA added children aged 5 to 11 to the Pfizer program and children aged 6 through 17 to the Moderna one.

    Experts are concerned that the low number of vaccinations is due to a sense that the pandemic is over and no longer poses a major risk for most people. U.S. cases are steadily declining and now stand at their lowest level since mid-April; however, the true tally is likely higher than the official count, because many people are testing at home, where data are not being collected.

    The daily average for new cases stood at 37,649 on Sunday, down 19% from two weeks ago, according to a New York Times tracker.

    The daily average for hospitalizations was down 5% to 26,475, while the daily average for deaths was down 8% to 374.

    But cold weather is expected to bring a new wave of cases, and hospitalizations are rising again in much of the Northeast, the Times tracker is showing.

    “That’s the thing that’s so frustrating for me and for my colleagues who are involved in this, is that we have the capability of mitigating against this. And the uptake of the new bivalent vaccine is not nearly as high as we would like it to be,” said Fauci.

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Moderna and Gavi, the Vaccine Alliance, which is supplying vaccines to low- and middle-income countries, have agreed to cancel remaining orders under their 2022 COVID-19 vaccine agreement given “sufficient supply.” The biotechnology company has supplied Gavi with nearly 70 million doses of COVID-19 vaccines, in addition to facilitating the donation of more than 100 million doses. Moderna and Gavi said they will create a new framework that enables Gavi to buy up to 100 million COVID-19 vaccine doses in 2023. 

    • The World Health Organization, the Food and Agriculture Organization of the United Nations, the United Nations Environment Program and the World Organization for Animal Health on Monday launched a new initiative that aims to address health threats to humans, animals, plants and the environment. The One Health Joint Plan of Action “aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats,” the four agencies said in a statement.

    • China is doubling down on its zero-COVID strategy as a historic Communist Party congress opens in Beijing, BBC News reported. Zero COVID was a “people’s war to stop the spread of the virus,” said President Xi Jinping as he kicked off the meeting. There is increasing public fatigue over lockdowns and travel restrictions, and Beijing has come under strict security measures ahead of the congress, sparking frustration in the city, including a rare and dramatic public protest on Thursday criticizing Xi and his strategy.

    In a rare display of defiance, two banners were unfurled from a highway overpass in Beijing condemning Chinese President Xi Jinping and his strict COVID-19 policies. The protest took place days before the expected extension of Xi’s tenure.

    • Airline stocks rallied Monday after data showed that on Sunday, more people flew than on any other day since before the pandemic. Data from the Transportation Security Administration showed that 2.495 million travelers went through TSA checkpoints on Sunday, which is just above the previous 2022 high of 2.490 million on July 1 and the most since Feb. 11, 2020, which was exactly one month before the World Health Organization declared COVID-19 a global pandemic. In comparison, the day with the fewest travelers since the start of the pandemic was April 12, 2022, with 87,534 people traveling. And in 2019, there were 116 days of more travelers than Sunday, while the average for that year was 2.306 million. The U.S. Global Jets ETF
    JETS,
    +2.02%

     was up 2.2%.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 624.7 million on Monday, while the death toll rose above 6.56 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 96.9 million cases and 1,065,118 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 226.2 million people living in the U.S., equal to 68.1% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 110.8 million have had a booster, equal to 49% of the vaccinated population, and 25.6 million of those who are eligible for a second booster have had one, equal to 39% of those who received a first booster.

    [ad_2]

    Source link

  • Study finds Paxlovid can interact badly with some heart medications, and White House renews COVID emergency through Jan. 11

    Study finds Paxlovid can interact badly with some heart medications, and White House renews COVID emergency through Jan. 11

    [ad_1]

    A new study has found that the COVID antiviral Paxlovid can interact badly with certain heart medications, raising concerns for patients with cardiovascular risk who test positive.

    The study was published in the Journal of the American College of Cardiology and found the reaction involved such medications as blood thinners and statins. As patients who are hospitalized with COVID are at elevated risk of heart problems, they are likely to be described Paxlovid, which was developed by Pfizer
    PFE,
    -0.45%
    .

     “Co-administration of NMVr (Paxlovid) with medications commonly used to manage cardiovascular conditions can potentially cause significant drug-drug interactions and may lead to severe adverse effects,” the authors wrote. “It is crucial to be aware of such interactions and take appropriate measures to avoid them.”

    The news comes just days after the White House made a renewed push to encourage Americans above the age of 50 to take Paxlovid or use monoclonal antibodies if they test positive and are at risk of developing severe disease.

    White House coordinator Dr. Ashish Jha told the New York Times that greater use of the medicine could reduce the average daily death count to about 50 a day from close to 400 currently.

    “I think almost everybody benefits from Paxlovid,” Jha said. “For some people, the benefit is tiny. For others, the benefit is massive.” 

    Yet a smaller share of 80-year-olds with COVID in the U.S. is taking it than 45-year-olds, Jha said, citing data said he has seen.

    On Thursday, the White House extended its COVID pubic health emergency through Jan. 11 as it prepares for an expected rise in cases in the colder months, the Associated Press reported.

    The public health emergency, first declared in January 2020 and renewed every 90 days since, has dramatically changed how health services are delivered.

    The declaration enabled the emergency authorization of COVID vaccines, as well as free testing and treatments. It expanded Medicaid coverage to millions of people, many of whom will risk losing that coverage once the emergency ends. It temporarily opened up telehealth access for Medicare recipients, enabling doctors to collect the same rates for those visits and encouraging health networks to adopt telehealth technology.

    Since the beginning of this year, Republicans have pressed the administration to end the public health emergency.

    President Joe Biden, meanwhile, has urged Congress to provide billions more in aid to pay for vaccines and testing. Amid Republican opposition to that request, the federal government ceased sending free COVID tests in the mail last month, saying it had run out of funds for that effort.

    Separately, the head of the World Health Organization urged countries to continue to surveil, monitor and track COVID and to ensure poorer countries get access to vaccines, diagnostics and treatments, reiterating that the pandemic is not yet over.

    Tedros Adhanom Ghebreyesus said most countries no longer have measures in place to limit the spread of the virus, even though cases are rising again in places including Europe.

    “Most countries have reduced surveillance drastically, while testing and sequencing rates are also much lower,” Tedros said in opening remarks at the IHR Emergency Committee on COVID-19 Pandemic on Thursday.

    “This,” said the WHO leader, “is blinding us to the evolution of the virus and the impact of current and future variants.”

    U.S. known cases of COVID are continuing to ease and now stand at their lowest level since late April, although the true tally is likely higher given how many people overall are testing at home, where the data are not being collected.

    The daily average for new cases stood at 38,530 on Thursday, according to a New York Times tracker, down 19% from two weeks ago. Cases are rising in six states, namely Nevada, New Mexico, Kansas, Maine, Wisconsin and Vermont, and are flat in Wyoming. They are falling everywhere else.

    The daily average for hospitalizations was down 7% at 26,665, while the daily average for deaths is down 7% to 377. 

    The new bivalent vaccine might be the first step in developing annual Covid shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to Covid could be challenging. Illustration: Ryan Trefes

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Federal Health Minister Karl Lauterbach has urged German states to reintroduce face-mask requirements for indoor spaces due to high COVID cases numbers, the Local.de reported. Lauterbach was launching his ministry’s new COVID campaign on Friday. “The direction we are heading in is not a good one,” he said at a press conference in Berlin, adding it’s better to take smaller measures now than be forced into drastic ones later.

    • Health officials in Washington and Oregon said Thursday that a fall and winter COVID surge is likely headed to the Pacific Northwest after months of relatively low case levels, the AP reported. King County (Wash.) Health Officer Dr. Jeff Duchin said during a news briefing that virus trends in Europe show a concerning picture of what the U.S. could soon see, the Seattle Times reported.

    Two banners unfurled from a highway overpass in Beijing condemned Chinese President Xi Jinping and his strict Covid policies, in a rare display of defiance. The protest took place days before the expected extension of the leader’s tenure.

    • Kevin Spacey’s trial on sexual-misconduct allegations will continue without a lawyer who tested positive for COVID on Thursday, Yahoo News reported. The “American Beauty” and “House of Cards” star is on trial in Manhattan federal court facing allegations in a $40 million civil lawsuit that he preyed upon actor Anthony Rapp in 1986 when Rapp was 14 and Spacey was 26. Jennifer Keller’s diagnosis comes after she spent about five hours cross-examining Rapp on the witness stand over two days — a few feet away from the jury box without wearing a mask.

    • A man who presents himself as an Orthodox Christian monk and an attorney with whom he lived fraudulently obtained $3.5 million in federal pandemic relief funds for nonprofit religious organizations and related businesses they controlled, and spent some of it to fund a “lavish lifestyle,” federal prosecutors said Thursday. Brian Andrew Bushell, 47, and Tracey M.A. Stockton, 64, are charged with conspiracy to commit wire fraud and unlawful monetary transactions, the U.S. attorney’s office in Boston said in a statement, as reported by the AP.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 623.9 million on Monday, while the death toll rose above 6.56 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 96.9 million cases and 1,064,821 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 226.2 million people living in the U.S., equal to 68.1% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 110.8 million have had a booster, equal to 49% of the vaccinated population, and 25.6 million of those who are eligible for a second booster have had one, equal to 39% of those who received a first booster.

    Some 14.8 million people have had a shot of the new bivalent booster that targets the new omicron subvariants.

    [ad_2]

    Source link

  • Moderna Stock Takes Off on Cancer Vaccine News

    Moderna Stock Takes Off on Cancer Vaccine News

    [ad_1]



    Moderna


    stock shot up after


    Merck


    said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker.

    Merck (ticker: MRK) will pay


    Moderna


    (MRNA) $250 million for the joint development and future commercialization of the vaccine, which is currently in Phase 2 clinical trials. The two companies had announced a “strategic collaboration” in June 2016.

    [ad_2]

    Source link

  • Large number of U.S. COVID deaths could be prevented if patients would take Pfizer’s Paxlovid, White House coordinator warns

    Large number of U.S. COVID deaths could be prevented if patients would take Pfizer’s Paxlovid, White House coordinator warns

    [ad_1]

    A large number of U.S. COVID deaths could be prevented if patients would take Paxlovid, the antiviral developed by Pfizer
    PFE,
    -1.79%

    that helps reduce the risk of hospitalization and death, according to White House COVID coordinator Dr. Ashish Jha.

    Jha told the New York Times that the average daily death count could be reduced to about 50 a day from 400 currently, if every American aged 50 and above that tests positive for the virus took a course of either Paxlovid or used monoclonal antibodies.

     “The public doesn’t seem to understand that the evidence around hospitalization and deaths is really powerful,” Dr. Robert Wachter, chair of medicine at the University of California in San Francisco told the paper.

    The issue seems to be a combination of worry about certain issues that Paxlovid can cause, including a strange metallic taste and the potential for “rebound COVID,” where patients quickly become reinfected after the five-day course of pills has been completed. That happened to both President Joe Biden and first lady Jill Biden recently.

    The second reason is that many Americans — and Republicans, in particular — have refused to take COVID seriously and are not willing to take steps to reduce its impact. Trials have found Paxlovid to be effective across all age groups, but mostly among older patients. But as the COVID death rate for people under 50 is already close to zero, reducing it in a statistically significant way is difficult.

    See now: CDC scraps travel health notices as countries slow testing, and study confirms Republican-leaning counties suffered more COVID deaths than Democrat-leaning ones

    “I think almost everybody benefits from Paxlovid,” Jha said. “For some people, the benefit is tiny. For others, the benefit is massive.” 

    Yet a smaller share of 80-year-olds with COVID in the U.S. is taking it than 45-year-olds, Jha said citing data he has seen.

    From the CDC: Stay Up to Date with COVID-19 Vaccines Including Boosters

    The news comes as U.S. known cases of COVID are continuing to ease and now stand at their lowest level since late April, although the true tally is likely higher given how many people are testing at home, with data generally not being collected.

    The daily average for new cases stood at 41,605 on Thursday, according to a New York Times tracker, down 25% from two weeks ago. Cases are declining in northeastern states including New York and New Jersey, while cases are rising in the western states Montana, Washington and Oregon.

    The daily average for hospitalizations was down 11% at 27,021, while the daily average for deaths is down 8% to 391.

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Molnupiravir, the COVID pill developed by Merck
    MRK,
    +0.18%

    and privately held Ridgeback Therapeutics, produced mixed results in two recent studies, the companies said Thursday. Early data from a trial conducted in the U.K. by the University of Oxford found no evidence of a difference when molnupiravir was added to usual care in reducing hospitalizations and death. A second study conducted in Israel found a benefit in patients who were 65 and older, but no benefit for 40- to 60-year-olds.

    • Homelessness is surging in the U.S. again as pandemic programs that halted evictions are being phased out, the Associated Press reported. The overall number of homeless people in a federal report to be released in the coming months is expected to be higher than the 580,000 unhoused before the coronavirus outbreak, the National Alliance to End Homelessness said. The AP tallied results from city-by-city surveys conducted earlier this year and found the number of people without homes is up overall compared with 2020 in areas reporting results so far.

    • The idea was to have China in stable and tip-top shape when thousands of delegates gather in Beijing to usher in a historic third term in power for Xi Jinping, BBC News reported. However, the coronavirus is not playing nicely. In recent weeks, tens of millions of people have again been confined to their homes in lockdowns across 60 towns and cities, and this is bringing political pressure on the man who has become the most powerful Chinese figure since the first communist-era leader, Mao Zedong.

    Covid-19 lockdowns, corruption crackdowns and more have put China’s economy on a potential crash course. WSJ’s Dion Rabouin explains how China’s economic downturn could harm the U.S. and the rest of the world. Illustration: David Fang

    • A new COVID-19 wave appears to be brewing in Europe as cooler weather arrives, with public health experts warning that vaccine fatigue and confusion over types of available vaccines will likely limit booster uptake, Reuters reported. The omicron subvariants BA.4 and BA.5 that dominated this summer are still behind the majority of infections, but newer omicron subvariants are gaining ground. Hundreds of new forms of omicron are being tracked by scientists, the World Health Organization said this week.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 620.5 million on Friday, while the death toll rose above 6.55 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 96.6 million cases and 1,062,130 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 225.8 million people living in the U.S., equal to 68% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 110.5 million have had a booster, equal to 48.9% of the vaccinated population, and 24.8 million of those who are eligible for a second booster have had one, equal to 37.9% of those who received a first booster.

    Some 11.5 million people have had a shot of the new bivalent booster that targets the new omicron subvariants.

    [ad_2]

    Source link

  • U.S. risks prolonging pandemic if it doesn’t back WTO push to get vaccines and treatments to lower-income countries, lawmakers warn

    U.S. risks prolonging pandemic if it doesn’t back WTO push to get vaccines and treatments to lower-income countries, lawmakers warn

    [ad_1]

    The U.S. is at risk of prolonging the COVID pandemic if it fails to back an initiative that aims to get vaccines, diagnostics and treatments to lower-income countries, a congressional group has told President Joe Biden.

    In a letter to Biden from the group led by Earl Blumenauer, a Democrat from Oregon, the group urged him to back the World Trade Organization’s agreement in June to ease exports of lifesaving therapies.

    With more than 600 million shots in arms, 21,500 free testing sites, the ability to order at-home tests for free, and more treatments available now than at any point in the pandemic, the outlook in the United States is better than ever. Unfortunately, however, the prospect for many low-income countries is not so positive — putting the United States’ own success in jeopardy,” the lawmakers wrote.

    The letter was sent ahead of a meeting of the WTO council for trade-related aspects of IP rights that is due to kick off Thursday.

    The group noted that lower-income countries are facing a higher risk of severe illness, hospitalization and death as only a small percentage of their populations are vaccinated. Just 19% of people in those countries are vaccinated, compared with about 75% in high-income countries, according to the Multilateral Leaders Taskforce on COVID-19, a joint initiative of the International Monetary Fund, the World Bank, the World Health Organization and the WTO.

    U.S. known cases of COVID are continuing to ease and now stand at their lowest level since late April, although the true tally is likely higher given how many people are testing at home, where the data are not being collected.

    The daily average for new cases stood at 43,149 on Wednesday, according to a New York Times tracker, down 23% from two weeks ago. Cases are rising in most northeastern states by 10% of more, while cases in the western states Montana, Washington and Oregon are rising.

    The daily average for hospitalizations was down 11% at 27,184, while the daily average for deaths is down 8% to 391. 

    The new bivalent vaccine might be the first step in developing annual Covid shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to Covid could be challenging. Illustration: Ryan Trefes

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • China’s huge Xinjiang region has been hit with sweeping COVID travel restrictions ahead of a key Communist Party congress later this month, the Associated Press reported. Trains and buses in and out of the region of 22 million people have been suspended, and passenger numbers on flights have been reduced to 75% of capacity in recent days, according to Chinese media reports. The region is home to minorities who have been forced into prison-like re-education centers to force them to renounce their religion, typically Islam, and allegedly subjected to human-rights abuses.

    • Five current or former Internal Revenue Service workers have been charged with fraud for illegally getting money from federal COVID-19 relief programs and using a total of $1 million for luxury items and personal trips, prosecutors said, the AP reported. The U.S. attorney’s office in Memphis said Tuesday that the five have been charged with wire fraud after they filed fake applications for the Paycheck Protection Program and the Economic Injury Disaster Loan Program, which were part of a federal stimulus package tied to the pandemic response in 2020.

    • Peloton Interactive Inc.
    PTON,
    +3.84%

    said it plans to cut about 500 jobs, roughly 12% of its remaining workforce, in the company’s fourth round of layoffs this year as the connected fitness-equipment maker tries to reverse mounting losses, the Wall Street Journal reported. After enjoying a strong run early on in the pandemic, Peloton has struggled since the start of the U.S. recovery, and CEO Barry McCarthy, who took over in February, said he is giving the unprofitable company another six months or so to significantly turn itself around and, if it fails, Peloton likely isn’t viable as a stand-alone company.

    Don’t missPeloton CEO says ‘naysayers’ are looking at the company’s $1.2 billion quarterly loss all wrong.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 619.9 million on Wednesday, while the death toll rose above 6.55 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 96.6 million cases and 1,061,490 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 225.3 million people living in the U.S., equal to 67.9% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 109.9 million have had a booster, equal to 48.8% of the vaccinated population, and 23.9 million of those who are eligible for a second booster have had one, equal to 36.6% of those who received a first booster.

    Some 7.6 million people have had a shot of one of the new bivalent boosters that target the new omicron subvariants that have become dominant around the world.

    [ad_2]

    Source link

  • A strong fall COVID booster campaign could save 90,000 U.S. lives and avoid more than 936,000 hospitalizations, study finds

    A strong fall COVID booster campaign could save 90,000 U.S. lives and avoid more than 936,000 hospitalizations, study finds

    [ad_1]

    A strong fall COVID booster campaign could save about 90,000 people living in the U.S. from dying of the virus and avoid more than 936,000 hospitalizations, according to a new study by the Commonwealth Fund.

    As immunity wanes and new variants that can evade protection from early vaccines emerge, surges in hospitalizations and deaths are increasingly likely this fall and winter, the authors wrote. That makes it important that people get the bivalent boosters recently authorized by the Food and Drug Administration and help stop transmission, they wrote.

    Researchers analyzed three scenarios to evaluate the impact of vaccination on reducing fatalities, hospitalizations and medical costs to both the Medicare and Medicaid programs.

    The first measured the outcome if daily vaccination rates remain unchanged from current levels; they have gradually declined since the first wave of the omicron variant. Federal financial support has also not been replenished, amid a perception among many Americans that the pandemic is over and as congressional Republicans oppose legislative efforts to continue the pandemic fight.

    As of Oct. 3, some 68% of the U.S. population has had primary shots, but fewer than half of those have received a booster dose, and only 36% of those aged 50 and older have had a second booster.

    The second and third Commonwealth Fund scenarios looked at outcomes if rates increased by the end of 2022.

    In one scenario, researchers imagined booster uptake would track flu-shot coverage in 2020 to 2021. The other scenario assumed 80% of eligible individuals 5 and older get a booster by the end of 2022.


    Source: Commonwealth Fund

    The data found that more than 75,000 deaths could be prevented along with more than 745,000 hospitalizations if coverage reaches similar levels to 2021 to 2022 flu vaccination. The best scenario would save $56 billion in direct medical costs over the course of the next six months.

    “Stratifying by insurance type, we found direct medical costs would be reduced by $11 billion for Medicare alone under scenario 1 and $13 billion under scenario 2,” the authors wrote. “An additional $3.5 to $4.5 billion in savings would accrue to Medicaid. Even if the federal government paid all vaccination costs, accelerated campaigns would generate more than $10 billion in net savings from federal programs like Medicare and Medicaid.”

    The study comes as U.S. known cases of COVID are continuing to ease and now stand at their lowest level since late April, although the true tally is likely higher given how many people are testing at home, with data not being collected.

    The daily average for new cases stood at 44,484 on Tuesday, according to a New York Times tracker, down 22% from two weeks ago. Cases are rising in most northeastern states by 10% of more, while cases in the are rising in the western states Montana, Washington and Oregon.

    The daily average for hospitalizations was down 12% at 27,334, while the daily average for deaths is down 8% to 393. 

    The new bivalent vaccine might be the first step in developing annual Covid shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to Covid could be challenging. Illustration: Ryan Trefes

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Long COVID, a condition that can encompass symptoms such as respiratory distress, cough, “brain fog,” fatigue and malaise that last 12 weeks or longer after initial infection, is becoming a long-term challenge as both employers and workers navigate an ever-mutating virus, according to Liz Seegert, writing for NextAvenue.org. The Centers for Disease Control and Prevention found that one in five COVID survivors younger than 65 experienced at least one incident that might be related to previous COVID-19 infection. Among those 65 and older, the rate was one in four. Their data also show that nearly three times as many people age 50 to 59 currently have long COVID than those 80 or older.

    • A retired judge opened a public inquiry on Tuesday into how Britain handled the coronavirus pandemic, saying bereaved families and those who suffered would be at the heart of the proceedings, the Associated Press reported. Former Court of Appeal judge Heather Hallett said the inquiry would investigate the U.K.’s preparedness for a pandemic, how the government responded, and whether the “level of loss was inevitable or whether things could have been done better.”

    With each mutation, the Covid-19 virus is becoming more transmissible. WSJ’s Daniela Hernandez breaks down the science of how Covid variants are getting better at infecting and spreading. Illustration: Rami Abukalam

    • Health experts are keeping an eye on new versions of the BA.5 omicron subvariant amid concerns those virus versions can evade the drugs developed to fight COVID, Salon reported. Of particular concern are two named BQ.1 and BQ.1.1, along with BA.2.75.2, which is spreading in Singapore, India and parts of Europe. Then there’s XBB, which some research suggest is the most antibody-evasive strain tested so far. The World Health Organization said in its weekly update on the virus that BA.5 descendent lineages continued to be dominant in the latest week, accounting for 80.8% of sequences shared through a global database. It also noted “increased diversity” within omicron and its lineages.

    • Eiger BioPharmaecuticals Inc.
    EIGR,
    -5.01%

    said Wednesday it will not pursue emergency authorization of its experimental treatment for mild and moderate COVID-19 infections. It had asked the Food and Drug Administration to consider an EUA application based on data from the Together trial, a Phase 3 study that has assessed 11 possible treatments for COVID-19 that is being conducted in Brazil and Canada. Eiger said the FDA instead recommended the company consider running its own pivotal trial for peginterferon lambda that would support full approval of the drug.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 619.2 million on Wednesday, while the death toll rose above 6.55 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 96.5 million cases and 1,060,446 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 225.3 million people living in the U.S., equal to 67.9% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 109.9 million have had a booster, equal to 48.8% of the vaccinated population, and 23.9 million of those who are eligible for a second booster have had one, equal to 36.6% of those who received a first booster.

    Some 7.6 million people have had a shot of the new bivalent booster that targets the new omicron subvariants that have become dominant around the world.

    [ad_2]

    Source link

  • What Doctors Still Don’t Understand About Long COVID

    What Doctors Still Don’t Understand About Long COVID

    [ad_1]

    As a pulmonary specialist, I spend most of my clinical time in the hospital—which, during pandemic surges, has meant many long days treating critically ill COVID-19 patients in the ICU. But I also work in an outpatient clinic, where I also treat those same sorts of patients after they’re discharged: people who survived weeks-long hospitalizations but have been dealing ever since with lung damage. Such patients often face the same social and economic factors that made them vulnerable to COVID-19 to begin with, and they require attentive care.

    Patients like these undoubtedly suffer what researchers have been calling post-acute sequelae of SARS-CoV-2, or PASC—which, according to one highly publicized recent CDC study, afflicts some 20 percent of COVID-19 survivors ages 18 to 64. Other studies have yielded lower estimates of the condition also called long COVID, and while differences in study methodology account for some of this variability, there’s a more fundamental issue eluding efforts to uncover the one “true” estimate of the likelihood of this condition. Quite simply, long COVID isn’t any one thing.

    The wide spectrum of conditions that fall under the umbrella of long COVID impedes researchers’ ability to interpret estimates of national prevalence based on surveys of symptoms, which conflate different problems with different causes. More importantly, however, an incomplete and constrained perspective on what long COVID is or isn’t limits Americans’ understanding of who is suffering and why, and of what we can do to improve patients’ lives today.

    The cases of long COVID that turn up in news reports, the medical literature, and in the offices of doctors like me fall into a few rough (and sometimes overlapping) categories. The first seems most readily explainable: the combination of organ damage, often profound physical debilitation, and poor mental health inflicted by severe pneumonia and resultant critical illness. This serious long-term COVID-19 complication gets relatively little media attention despite its severity. The coronavirus can cause acute respiratory distress syndrome, the gravest form of pneumonia, which can in turn provoke a spiral of inflammation and injury that can end up taking down virtually every organ. I have seen many such complications in the ICU: failing hearts, collapsed lungs, failed kidneys, brain hemorrhages, limbs cut off from blood flow, and more. More than 7 million COVID-19 hospitalizations occurred in the United States before the Omicron wave, suggesting that millions could be left with damaged lungs or complications of critical illness. Whether these patients’ needs for care and rehabilitation are being adequately (and equitably) met is unclear: Ensuring that they are is an urgent priority.

    Recently, a second category of long COVID has made headlines. It includes the new onset of recognized medical conditions—like heart disease, a stroke, or a blood clot—after a mild COVID-19 infection. It might seem odd that an upper respiratory tract infection could trigger a heart attack. Yet this pattern has been well described after other common respiratory-virus infections, particularly influenza. Similarly, various types of infections can lead to blood clots in the legs, which can travel (dangerously) to the lungs. Respiratory infections are not hermetically sealed from the rest of the body; acute inflammation arising in one location can sometimes have consequences elsewhere.

    But mild COVID-19 is so common that measuring the prevalence of such complications—which also regularly occur in people without COVID-19—can be tricky. Well-controlled investigations are needed to disentangle causation and correlation, particularly because social disadvantage is associated both with COVID exposure and illnesses of basically every organ system. Some such studies, which analyzed giant electronic-health-record databases, have suggested that even mild COVID-19 is at least correlated with a startlingly wide spectrum of seemingly every illness, including diabetes, asthma, and kidney failure; basically every type of heart disease; alcohol-, benzodiazepine-, and opioid-use disorders; and much more.

    To be clear, this research generally suggests that such complications occur far less often after mild COVID-19 cases than severe ones, and the extent to which the coronavirus causes each such complication remains unclear. In other words, we can surmise that at least some of these complications (particularly vascular complications, which have been well-described in many studies) are likely a consequence of COVID-19, but we can’t say with certainty how many. And more importantly, we don’t yet understand why some people with mild COVID recover easily while others go on to experience such complications. However, an estimated 81 percent of Americans have now been infected at least once, so the public-health ramifications are large even if COVID causes only some of the aforementioned recognized diseases, and even if our individual risk of complications after a mild infection is modest. Regardless of cause, patients who do develop any such chronic diseases require attentive, ongoing medical care—a challenge in a nation where 30 million are uninsured and even more underinsured.

    Another category of long COVID is something rather more quotidian, if still very distressing for those experiencing it: respiratory symptoms that last longer than expected after an acute upper-respiratory infection caused by the coronavirus, but that are not associated with lung damage, critical illness, or a new diagnosis like a heart attack or diabetes. Symptoms such as shortness of breath and chest pain are common months after run-of-the-mill pneumonia unconnected to the coronavirus, for instance, while many patients who contract non-COVID-related upper respiratory infections subsequently report a protracted cough or a lingering loss of their sense of smell. That a COVID-related airway infection sometimes has similar consequences only stands to reason.

    However, none of these may be what most people think of when long COVID is invoked. Some may even argue that such syndromes are not, in fact, long COVID at all, even if they cause long-term suffering. “Long Covid is not a condition for which there are currently accepted objective diagnostic tests or biomarkers,” wrote Steven Phillips and Michelle Williams in the New England Journal of Medicine. “It is not blood clots, myocarditis, multisystem inflammatory disease, pneumonia, or any number of well-characterized conditions caused by Covid-19.” Instead, for some the term may invoke a chronic illness—a complex of numerous unexplained, potentially debilitating symptoms—even among those who may barely have felt sick with COVID in the acute phase. Symptoms may vary widely, and include severe fatigue, cognitive issues often described as brain fog, shortness of breath, “internal tremors,” gastrointestinal problems, palpitations, dizziness, and many other issues around the body—all typically following a mild acute respiratory infection. If the other forms of long COVID seem more easily explainable, this type is often characterized as a medical mystery.

    Teasing apart which kind of long COVID a person has is important, both to advance our understanding of the illness and to best care for people. Yet lumping and splitting varieties of long COVID into categories is not easy. A given patient’s case might have features of more than one of the types that I’ve described here. Some patient advocates and researchers have tended to exclude patients in the first category—that is, survivors of protracted critical illness—from their conception of COVID long-haulers. I would argue that, insofar as we define long COVID as lasting damage and symptoms imposed by SARS-CoV-2, the full variety of severe long-term manifestations should be included in its scope. “Clinical phenotyping” studies now under way may eventually help scientists and doctors better understand the needs of different types of patients, but patients in all categories deserve better care today.

    The biological mechanisms by which an acute coronavirus upper respiratory infection might lead to a bewildering range of chronic, burdensome symptoms even in the aftermath of mild infections are debated. Some scientists, for instance, believe that the virus causes an autoimmune disease akin to lupus. Meanwhile, one group of researchers has argued that even a mild respiratory infection from SARS-CoV-2 causes tiny clots to block tiny blood vessels all over the body, depriving tissues of oxygen throughout the body. Still others believe that the coronavirus causes a chronic infection, as such viruses as HIV or hepatitis C do. Meanwhile, some have emphasized the possibility of structural brain damage. While some published studies have provided support for each theory, none has been adequately validated as a central unifying thesis. Each is, however, worth continuing to explore.

    A recently published investigation, conducted at the National Institutes of Health, suggests that clinicians and scientists should consider additional possibilities as potential drivers of symptoms for at least some patients. The researchers found far higher levels of physical symptoms and mental distress among subjects who had had COVID (many with long COVID) than among those who had not. Yet symptoms could not be explained by basically any test results: Researchers found effectively no substantive differences in markers of inflammation or immune activation, in objective neurocognitive testing, or in heart, lung, liver, or kidney function. And yet these patients were suffering from such symptoms as fatigue, shortness of breath, concentration and memory problems, chest pain, and more. Notably, researchers did not identify viral persistence in the bodies of patients reporting troublesome symptoms.

    What this means in practice is that there are some people suffering from long COVID symptoms without evidence of structural damage to the body, autoimmunity, or chronic infection. Psychosocial strain and suffering, moreover, appears common in this population. Even pointing this out is sensitive territory—it leads some people to wrongly suggest that long COVID is less severe or concerning than those suffering from it describe, or even to question the reality of the illness. And, understandably, the invocation of psychosocial factors as potential contributing factors to suffering for some individuals may make patients feel as though they are being second-guessed. The reality, though, is that psychosocial strain is an important driver of physical symptoms and suffering—one that clinicians should treat with empathy. All suffering, after all, is ultimately produced and perceived in one place: our brain.

    Severe depression, for instance, can inflict debilitating and severe physical symptoms of every sort, including crushing fatigue and withering brain fog, and is itself linked to having had COVID-19. And notably, a recent study in JAMA Psychiatry found that pre-infection psychosocial distress—e.g. depression, anxiety, or loneliness—was associated with a 30–50 percent increase in the risk of long COVID among those infected, even after adjustment for various factors. A false separation of brain and body has long plagued medicine, but it does not reflect biological reality: After all, diverse neuropsychiatric processes are associated with numerous “physical” changes, ranging from reduced blood flow to the brain to high (or low) levels of the stress hormone cortisol.

    Illnesses of any cause that result in protracted time off one’s feet can also instigate (likely in conjunction with other factors) reversible cardiovascular deconditioning, wherein the blood volume contracts and the amount of blood ejected by the heart with each squeeze falls—changes that can lead to a racing heart rate or faintness when standing, as decades of studies have shown. Diverse neurological symptoms can also be produced by a glitch in the function rather than the structure of the brain—or what has been described as problems of brain “software” rather than “hardware”—resulting in conditions known as functional neurological disorders. Similar glitches, known as functional respiratory disorders, can disturb our breathing patterns or cause shortness of breath, even when our lungs are structurally normal. My point is not to speculate on some overarching hypothesis to explain all symptoms among all patients with long COVID. The whole point is that there’s unlikely to be just one. And there is still much to learn.

    Research is underway to better understand this spectrum of illnesses, and their causes. But whichever diverse factors might be contributing to patients’ symptoms, we can take steps—both among clinicians and as a society—to improve lives now. Social supports can be as important as medical interventions: For those unable to work, qualification for disability assistance should not depend on a particular lab or lung-function test result. All patients with long-COVID symptoms deserve and require high-quality medical care without onerous cost barriers that may bankrupt them, which further compounds suffering. Universal healthcare is, that is to say, desperately needed to respond to this pandemic and its aftermath.

    Additionally, while no specific long-COVID medications have emerged, some treatments may be helpful for improving certain symptoms regardless of the specific type of illness, such as physical rehabilitative treatments for those with shortness of breath or reduced exercise tolerance. Ensuring universal access to such specialized rehabilitative care is essential as we enter the next stage of this pandemic. So is helping patients avoid the emerging cottage industry of dodgy providers hawking unproven long-COVID therapies. Health-care professionals also need more education about the broad spectrum of COVID-19-related issues, both to improve care and reduce stigmatization of patients with all types of this illness.

    Doctors and scientists still have much to learn about symptoms that continue—or first turn up—months or weeks after an initial COVID infection. What’s clear today is that long COVID can be many different things. That may confound our efforts to categorize it and discuss its implications, but the sheer variety should not get in the way of care for all who are suffering.

    [ad_2]

    Adam Gaffney

    Source link

  • CDC scraps travel health notices as countries slow testing, and study confirms Republican-leaning counties suffered more COVID deaths than Democrat-leaning ones

    CDC scraps travel health notices as countries slow testing, and study confirms Republican-leaning counties suffered more COVID deaths than Democrat-leaning ones

    [ad_1]

    The U.S. Centers for Disease Control and Prevention has dropped its country-by-country COVID-19 travel health notices that it began issuing early in the pandemic, the Associated Press reported. 

    The reason: Fewer countries are testing for the virus or reporting the number of COVID cases. That limits the CDC’s ability to calculate travelers’ risk, according to the agency.

    CDC spokeswoman Kristen Nordlund said the agency will only post a travel health notice for an individual country if a situation such as a troubling new variant of the virus changes CDC travel recommendations for that country.

    The CDC still recommends that travelers remain up-to-date on vaccines and follow recommendations found on its international travel page.

    From the CDC: Stay Up to Date with COVID-19 Vaccines Including Boosters

    A new study from the National Bureau of Economic Research has confirmed that political affiliations played a key role as a risk factor for dying of COVID, finding evidence that Republican-leaning counties suffered higher death rates than Democratic-leaning ones.

    “We estimate substantially higher excess death rates for registered
    Republicans when compared to registered Democrats, with almost all of the difference concentrated in the period after vaccines were widely available in our study states,” the authors, Jacob Wallace and Jason L. Schwartz of the Yale School of Public Health, and Paul Goldsmith-Pinkham of the Yale School of Management wrote.

    “Overall, the excess death rate for Republicans was 5.4 percentage points (pp), or 76%, higher than the excess death rate for Democrats.”

    The researchers used data from Ohio and Florida and matched 2017 voter registration data with mortality data from 2018 to 2021. They also found a link between political affiliation and views on vaccines, with Republican-leaning counties showing far lower vaccination rates.


    Source: NBER paper

    In the U.S., known cases of COVID are continuing to ease and now stand at their lowest level since late April, although the true tally is likely higher given how many people are testing at home, where the data are not being collected.

    The daily average for new cases stood at 45,495 on Monday, according to a New York Times tracker, down 24% from two weeks ago. Cases are rising in 11 states plus Washington, D.C. They are up by double-digit percentages in Rhode Island, Massachusetts and Vermont.

    The daily average for hospitalizations was down 11% at 27,854, while the daily average for deaths is down 12% to 386. 

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Norwegian Cruise Line Holdings Ltd.
    NCLH,
    +16.84%

    is removing all COVID testing, vaccination and masking requirements from its health and safety protocols. The company said the new protocols, which follows “significant, positive progress” in the public health environment, will be effective Oct. 4. “Health and safety are always our first priority; in fact, we were the health and safety leaders from the very start of the pandemic,” said Chief Executive Harry Sommer. “Many travelers have been patiently waiting to take their long-awaited vacation at sea and we cannot wait to celebrate their return.” 

    See also: Would you take a cruise without such COVID-19 testing, vaccination and masks? MarketWatch asked health experts to weigh in.

    • Ringo Starr has test positive for COVID, forcing the former Beatle to cancel scheduled concerts in Canada with his All Starr Band, the AP reported. Five concert dates from Tuesday to Sunday — in Winnipeg, Manitoba; Saskatoon, Saskatchewan; Lethbridge, Alberta; and the British Columbia cities of Abbotsford and Penticton — will be rescheduled. “Ringo hopes to resume as soon as possible and is recovering at home. As always, he and the All Starrs send peace and love to their fans and hope to see them back out on the road soon,” said a statement from the band.

    The new bivalent vaccine might be the first step in developing annual Covid shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to Covid could be challenging. Illustration: Ryan Trefes

    • A federal appeals court in New Orleans on Monday became the latest to hear arguments on whether President Joe Biden overstepped his authority with an order that federal contractors require that their employees be vaccinated against COVID, the AP reported separately. The contractor mandate has a complicated legal history. It is being challenged in more than a dozen federal court districts, and the mandate has been blocked or partially blocked in 25 states. 

    • The Chinese resort city of Sanya has ordered all tourists to take PCR tests, and those who fail to do so by noon on Tuesday will be slapped with a yellow code restricting their mobility, according to local officials, the South China Morning Post reported. The city in the southern province of Hainan logged two asymptomatic Covid-19 cases on Monday. It carried out a round of mass testing and locked down several areas in Haitang district, including a scenic island that received around 2,000 tourists on Monday.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 618.7 million on Tuesday, while the death toll rose above 6.54 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 96.4 million cases and 1,059,888 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 225.3 million people living in the U.S., equal to 67.9% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 109.9 million have had a booster, equal to 48.8% of the vaccinated population, and 23.9 million of those who are eligible for a second booster have had one, equal to 36.6% of those who received a first booster.

    Some 7.6 million people have had a shot of the new bivalent booster that targets the new omicron subvariants that have become dominant around the world.

     

    [ad_2]

    Source link

  • 1 in 5 of Americans don’t know about new omicron-targeting COVID boosters, survey finds

    1 in 5 of Americans don’t know about new omicron-targeting COVID boosters, survey finds

    [ad_1]

    About half of the American public has heard little or nothing about the new COVID-19 bivalent booster, a new survey by the Kaiser Family Foundation has found. The new booster targets the omicron variants that have become dominant around the world.

    One in five of those surveyed said they had heard “nothing at all” about the new boosters. Some 17% said they had heard “a lot” about the boosters, while 33% said they had heard “some” about the new shots. About a third said they’d already gotten the new booster or intended to do so as soon as possible.

    “Intention is somewhat higher among older adults, one of the groups most at risk for serious complications of a coronavirus infection,” the authors wrote. “Almost half (45%) of adults ages 65 and older say they have gotten the bivalent booster or intend to get it ‘as soon as possible.’”


    Source: Kaiser Family Foundation

    The news will likely disappoint health experts who cheered the regulatory authorization of the new boosters in August. The U.S. Food and Drug Administration granted emergency-use authorization to boosters developed by Moderna
    MRNA,
    +1.36%

    and by Pfizer
    PFE,
    -0.07%

    and German partner BioNTech
    BNTX,
    +1.53%

    for use in people aged 12 and older who have had an initial series of a COVID vaccine, including those who have already had one or more booster doses.

    The Centers for Disease Control and Prevention is recommending that all adults get one of the bivalent boosters at least two months after completing a primary series of shots. So far, some 7.6 million people in the U.S. have received it, according to the CDC.

    From the CDC: Stay Up to Date with COVID-19 Vaccines Including Boosters

    Once again, the country’s partisan divide is evident, with 6 in 10 Democrats saying they’ve already had the shot or will get it soon, compared with 1 in 8 Republicans.

    “Notably, 20% of Republicans say they will ‘definitely not’ get the new COVID-19 booster dose, while a further 38% of Republicans are unvaccinated or only partially vaccinated and therefore not eligible for the new updated COVID-19 booster dose,” the survey authors said.

    Also read: A common virus is putting more children in the hospital than in recent years

    In the U.S., known cases of COVID are continuing to ease and now stand at their lowest level since late April, although the true tally is likely higher given how many people are testing at home, where data are not being collected.

    The daily average for new cases stood at 47,569 on Thursday, according to a New York Times tracker, down 26% from two weeks ago and now at the lowest level since late April. Cases are rising in 14 states and are sharply higher in several. Montana leads the count with a 75% rise in the last two weeks, followed by Washington with a 48% rise. Cases are up by double digits in Rhode Island, New York, Massachusetts, New Hampshire, Vermont and New Jersey.

    The daily average for hospitalizations was down 13% to 28,639, while the daily average for deaths was down 11% to 407.

    The new bivalent vaccine might be the first step in developing annual COVID shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to COVID could be challenging. Illustration: Ryan Trefes

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • The U.K. is the only G-7 country whose economy is smaller now than before the pandemic, the Guardian reported, citing data released Friday by the Office for National Statistics. The ONS released figures showing that rather than the economy being 0.6% larger than it was in February 2020, a combination of a deeper recession during the pandemic and a weak recovery had left it 0.2% smaller. All the other major economies in the G-7, including France and Italy, recovered strongly enough to be larger than they were in February 2020.

    • Taiwan is the latest country to end mandatory COVID quarantines for people arriving from overseas, the Associated Press reported. Officials said that beginning Oct. 13, the previous weeklong quarantine requirement would be replaced with a seven-day self-monitoring period. A rapid antigen test will still be required upon arrival, but people showing no symptoms will be allowed to take public transportation. 

    • Germany’s health ministry is warning of a rise of COVID cases heading into the fall and is urging older people in particular to get a second booster shot, the AP reported separately. Other European countries such as France, Denmark and the Netherlands are also recording an increase in cases, German Health Minister Karl Lauterbach told reporters in Berlin. “We are clearly at the start of a winter wave,” he said.

    COVID-19 lockdowns, corruption crackdowns and more have put China’s economy on a potential crash course with the U.S. and the rest of the world, the Wall Street Journal’s Dion Rabouin explains. Illustration: David Fang

    • The first Chinese mRNA-based COVID vaccine has received government approval — in Indonesia, the New York Times reported. The shot, developed by Walvax Biotechnology
    300142,
    +0.49%
    ,
    Suzhou Abogen Biosciences and the Chinese military, was cleared this week by Indonesia for emergency use. Countries all over the world, including Indonesia, have embraced mRNA vaccines, and they are considered among the most effective vaccines that the world has to offer. But more than two years into the pandemic, they are not yet available in China, which has relied on an increasingly draconian “zero-COVID” approach to keep cases and deaths from the virus low.

    • Patriarch Kirill of Moscow, the head of the Russian Orthodox Church and a supporter of Russia’s war on Ukraine, has tested positive for COVID-19, the church’s press service said on Friday, Reuters reported. The church said Kirill, 75, a close ally of Russian President Vladimir Putin, had canceled all his planned trips and events and had “severe symptoms” requiring bed rest and isolation. It said his condition was “satisfactory.”

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 617.3 million on Friday, while the death toll rose above 6.54 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 96.3 million cases and 1,059,291 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 225.3 million people living in the U.S., equal to 67.9% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 109.9 million have had a booster, equal to 48.8% of the vaccinated population, and 23.9 million of those who are eligible for a second booster have had one, equal to 36.6% of those who received a first booster.

     

    [ad_2]

    Source link

  • A Simple Rule for Planning Your Fall Booster Shot

    A Simple Rule for Planning Your Fall Booster Shot

    [ad_1]

    In less than two weeks, you could walk out of a pharmacy with a next-generation COVID booster in your arm. Just a few days ago, the Biden administration indicated that the first updated COVID-19 vaccines would be available shortly after Labor Day to Americans 12 and older who have already had their primary series. Unlike the shots the U.S. has now, the new doses from Pfizer and Moderna will be bivalent, which means they’ll contain genetic material based both on the ancestral strain of the coronavirus and on two newer Omicron subvariants that are circulating in the U.S.

    These shots’ new formulation promises some level of protection that simply hasn’t been possible with the original vaccines. “A bivalent vaccine will have some benefit for almost everybody who gets it,” Rishi Goel, an immunologist at the University of Pennsylvania, told me. “How much benefit that is, we’re still not exactly sure.” People who aren’t at high risk could end up only marginally more protected against severe outcomes, and no one thinks the shots will banish COVID infections for good. There is, however, a simple rule of thumb that nearly everyone can follow to maximize the uncertain gains from a shot: Wait three to six months from your last COVID infection or vaccination.

    Put that rule into action, and it plays out a little differently, depending on your circumstances.

    If you haven’t had an Omicron infection:

    If you haven’t had COVID since about November 2021, the advantage of a bivalent booster over the original formula is obvious, and as long as you haven’t gotten boosted recently, there’s every reason to get the new one right away. (If you have been boosted in the past few months, your antibody levels are probably still too high for a new shot to do much for you.) Marion Pepper, an immunologist at the University of Washington, told me that Americans who have already gotten three or more doses “have probably maxed out the protective capacity” of the original shots. By contrast, the bivalent vaccines offer something new to those who have so far escaped Omicron: a lesson on the spike proteins of the BA.4 and BA.5 subvariants, which will help the immune system fight the real thing should it get into your body. “I’m just super excited to get the bivalent vaccine,” says Jenna Guthmiller, an immunologist at the University of Colorado who has not yet had COVID. “I think it’ll be really nice and ease my mind a little bit.”

    If you have had an Omicron infection:

    Veterans of Omicron infections might still have something to gain from seeing the BA.4 and BA.5 spike proteins—especially if your goal is to avoid getting sick with COVID at all. Past a certain number of shots, boosters’ impact on your long-term protection against severe disease is unclear, Goel told me. Paul Offit, the director of the Vaccine Education Center at Children’s Hospital of Philadelphia, told me he doesn’t plan on getting a booster at all this fall because, after three vaccine doses and an infection, “I think I’m protected against serious illness.” But if you want to stave off infection, Goel said, “the bivalent vaccines, or really any variant-containing vaccines, have real value.” That’s because formulas based on a given variant have been shown to temporarily increase your stock of antibodies that target that variant.

    How long that extra-protective state lasts, or whether it’s sufficient to prevent any infection whatsoever, is still a scientific puzzle. The original boosters were shown to increase antibody levels to a peak about two weeks after the shot, then decay steadily over the following three months. We don’t know yet whether a bivalent formula will change that timeline, Goel said.

    But you can still use it to estimate approximately when your protection will be at its highest. You might, for example, choose to err on the early side of that three-to-six-month timeline if you have a particularly high-risk event coming up in the next few weeks. “If all we had was the original booster and I was going to an indoor wedding or something, I think it would be reasonable to get that booster,” Pepper said.

    If you had an Omicron infection this summer:

    “You’re still riding the wave of antibodies that you generated as a result of that infection,” Guthmiller told me, so a shot won’t do much for you yet. That’s true regardless of which Omicron subvariant you might have been infected with, she said, because BA.2 infections have been shown to protect fairly well against today’s dominant strains, BA.4 and BA.5. (BA.2 became dominant in the United States back in March.) The severity of your illness doesn’t really matter either, Goel said. A higher fever and more intense cough might indicate that your immune system got extra revved up, he said, but they could just as easily mean that your body needs more help responding to the coronavirus. In either case, once a little more time has passed, getting the bivalent vaccine could help extend your body’s memory of its last COVID encounter, and keep infection at bay.

    If you’re at high risk:

    Certain groups of people should get any booster as soon as it’s available to them, the experts I spoke with emphasized to me: immunocompromised people, people over the age of 50 or so, and people with medical conditions that put them at high risk of severe disease. If you fall in one of these categories and haven’t received all the boosters you’re eligible for, “I wouldn’t wait for the bivalent,” Offit said. For people in these high-risk categories who have already gotten the recommended number of boosters, you should get the new one as soon as it’s available to you. (The FDA and CDC have not yet indicated whether they will recommend a waiting period between your most recent shot and the bivalent booster.) Goel recommended waiting at least a month after your most recent infection or shot, but if you’re very worried about your risk, you don’t need to stretch the delay to three months. Your body might still have extra antibodies floating around, but with no practical way to check at scale, “I’m honestly in favor of recommending boosting as a way to maximize individual benefit,” he said.

    If you want to wait and see:

    Waiting is always an option if you want to know more about how the bivalent vaccines perform. The FDA and CDC are set to green-light the shots based on human data from the existing boosters and other experimental bivalent boosters that didn’t make it to market in the U.S.—plus trials on the new formula in mice. Pfizer and Moderna simply haven’t progressed very far in their human trials. While there’s no reason to suspect that the new shots won’t be safe, Offit recommended opting for the original boosters until more safety and efficacy data are available, which could be as soon as a couple of months after the rollout—as long as the vaccine makers or the government collects that information and makes it public. But Guthmiller and Goel said they weren’t concerned about the lack of human data, and the bivalent shot is almost certainly the better bet.

    There is one significant reason to avoid waiting too long for the bivalent shot: It offers the greatest protection against infection from the subvariants it’s actually designed around. BA.4 and BA.5 might be with us through the fall and winter—or they might give way to a different branch of Omicron, or even a variant that’s entirely unlike Omicron. You’d certainly be better off against this new variant with a bivalent booster than no booster at all. But if you want to maximize your anti-infection shield while you have it, consider putting it up against the enemy you know.

    [ad_2]

    Rachel Gutman-Wei

    Source link